No Data
No Data
Shanghai Allist Pharmaceuticals' H1 Attributable Profit Triples; Shares Plunge 13%
Shanghai Allist Pharmaceuticals Co., Ltd. half-year report summary for 2024.
Shanghai Allist Pharmaceuticals Co., Ltd. Semi-Annual Report 2024
Innovative drugs also pays dividends! Shanghai Allist Pharmaceuticals Co., Ltd. earns 0.66 billion in the first half of the year and pays a generous dividend of 0.113 billion | Jiangu Intelligence Research.
The advantages of medical insurance are highlighted. In the first half of the year, the sales of Shanghai Allist Pharmaceuticals Co., Ltd.'s vemurafenib reached 1.555 billion. Sales expenses decreased quarter-on-quarter in the second quarter, with cash on hand exceeding 2.6 billion.
Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH): net income of 656 million yuan in the first half of the year, a year-on-year increase of 214.82%. Planned to distribute a dividend of 2.50 yuan per 10 shares.
Allist Pharmaceuticals Co., Ltd. (688578.SH) announced its semi-annual report for 2024, with revenue of CNY 1.576 billion, up 110.57% YoY; net income attributable to shareholders of the listed company was CNY 0.656 billion, up 214.82% YoY; diluted net income per share was CNY 1.46, and the net income attributable to shareholders of the listed company excluding non-recurring gains and losses was CNY 0.647 billion, up 251.94% YoY. The company plans to distribute a cash dividend of CNY 2.50 per 10 shares (including tax) based on the total share capital registered on the equity distribution registration date to all shareholders. Revenue increased.
Are Robust Financials Driving The Recent Rally In Shanghai Allist Pharmaceuticals Co., Ltd.'s (SHSE:688578) Stock?
No Data